E. Love

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors

H. Hochster, B. Levinson, D. Cohen, 2011, Cancer Chemotherapy and Pharmacology.

Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States

A. Balar, M. Abdul-Hay, K. Joseph, 2021, JCO oncology practice.

Racism and hypertension: a review of the empirical evidence and implications for clinical practice.

A. Schoenthaler, G. Ogedegbe, E. Brondolo, 2011, American journal of hypertension.

A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study.

J. Sparano, Y. Janjigian, E. Chan, 2013 .

Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.

J. Sparano, Y. Janjigian, P. Christos, 2013 .